Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission

Malaria Journal

Volumn 7, Issue , 2008, Pages

  Torres, Katherine J ^a   Clark, Eva H ^b   Hernandez, Jean N ^b   Soto Cornejo, Katherine E ^a   Gamboa, Dionicia ^a   Branch, OraLee H ^b  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CARBOXY TERMINAL TELOPEPTIDE; CHLOROQUINE; IMMUNOGLOBULIN G; MEFLOQUINE; MEROZOITE SURFACE PROTEIN 1; PRIMAQUINE; VACCINE; MALARIA VACCINE; PROTOZOON ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; PLASMODIUM FALCIPARUM; RANDOM SAMPLE; SEROPREVALENCE; ADOLESCENT; AGED; ANIMAL; BLOOD; ENDEMIC DISEASE; EPIDEMIOLOGY; IMMUNOLOGY; INFANT; MALARIA FALCIPARUM; MIDDLE AGED; PERU; PRESCHOOL CHILD; PREVALENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, PROTOZOAN; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; PERU; PLASMODIUM FALCIPARUM; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES;

EID: 53349097807     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-7-173     Document Type: Article

References (34)

1. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. JG Breman MS Alilio A Mills, Am J Trop Med Hyg 2004 71 2 Suppl 1 15 15331814
2. The global distribution and population at risk of malaria: past, present, and future. SI Hay CA Guerra AJ Tatem AM Noor RW Snow, Lancet Infect Dis 2004 4 327 336 10.1016/S1473-3099(04)01043-6 15172341
3. Human antibody response to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived. K Fruh OK Doumbo HM Muller O Koita JS McBride A Crisanti Y Toure H Bujard, Infect Immun 1991 59 1319 1324 2004813
4. A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. EM Riley S Morris-Jones MJ Blackman BM Greenwood AA Holder, Parasite Immunol 1993 15 513 524 10.1111/j.1365-3024.1993. tb00639.x 7877849
5. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. AF Egan J Morris G Brarnish S Allen BM Greenwood DC Kaslow AA Holder EM Riley, J Infect Dis 1996 173 765 769 8627050
6. A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. DR Cavanagh IM Elhassan C Roper VJ Robinson H Giha AA Holder L Hviid TG Theander DE Arnot JS McBride, J Immunol 1998 161 347 359 9647243
7. A longitudinal investigation of the IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. OH Branch V Udhayakumar AW Hightower AJ Oloo WA Hawley BL Nahlen PB Bloland DC Kaslow AA Lal, Am J Trop Med Hyg 1998 58 211 219 9502606
8. Short report: differential evolution of immunoglobulin G1/G3 antibody responses to Plasmodium falciparum MSP1(19) over time in malaria-immune adult Senegalese patients. TO Diallo A Spiegel A Dioug L Lochouarn DC Kaslow A Tall R Perraut O Garraud, Am J Trop Med Hyg 2002 66 137 139 12135282
9. The effects of varying exposure to malaria transmission on development of antimalarial antibody responses in preschool children. XVI. Asembo Bay Cohort Project. LM Singer LB Mirel FO ter Kuile OH Branch JM Vulule MS Kolczak WA Hawley SK Kariuki DC Kaslow DE Lanar AA Lal, J Infect Dis 2003 187 1756 1764 10.1086/375241 12751033
10. IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. SM Kinyanjui DJ Conway DE Lanar K Marsh, Malar J 2007 28 82 10.1186/1475-2875-6-82 17598897
11. A preliminary continental risk map for malaria mortality among African children. RW Snow MH Craig U Deichmann D le Sueur, Parasitol Today 1999 15 99 104 10.1016/S0169-4758(99)01395-2 10322322
12. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. OH Branch WM Casapia DV Gamboa JN Hernandez FF Alava N Roncal E Alvarez EJ Perez E Gotuzzo, Malar J 2005 23 27 10.1186/1475-2875-4-27
13. Endemic malaria in the Peruvian Amazon region of Iquitos. B Roshanravan E Kari RH Gilman L Cabrera E Lee J Metcalfe M Calderon AG Lescano SH Montenegro C Calampa JM Vinetz, Am J Trop Med Hyg 2003 69 45 52 12932096
14. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys. G Hui C Nikaido C Hashiro DC Kaslow WE Collins, Infect Immun 1996 64 1502 1509 8613353
15. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. SP Chang SE Case WL Gosnell A Hashimoto KJ Kramer LQ Tam CQ Hashiro CM Nikaido HL Gibson CT Lee-Ng PJ Barr BT Yokota GS Hut, Infect Immun 1996 64 253 261 8557348
16. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein-1 19 reveals a protective role for invasion inhibitory antibodies. TF de Koning-Ward RA O'Donnell DR Drew R Thomson TP Speed BS Crabb, J Exp Med 2003 198 869 875 12963693 10.1084/jem.20030085
17. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. CC John RA O'Donnell PO Sumba AM Moormann TF de Koning-Ward CL King JW Kazura BS Crabb, J Immunol 2004 173 666 672 15210830
18. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. S Singh K Miura H Zhou O Muratova B Keegan AP Miles LB Martin AJ Saul LH Miller CA Long, Infect Immun 2006 74 4573 4580 16861644 10.1128/IAI.01679-05
19. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. F al-Yaman B Genton KJ Kramer CS P HG S B M AM P, Am J Trop Med Hyg 1996 54 443 448 8644896
20. Phase 1 study of two merozoite surface protein 1 (MSP(42)) vaccines for Plasmodium falciparum malaria. E Malkin CA Long AW Stowers Z L S Singh NJ Macdonald DL Narum AP Miles AC Orcutt O Muratova SE Moretz H Zhou A Diouf M Fay E Tierney P Leese S Mahanty LH Miller A Saul LB Martin, PLoS Clin Trials 2007 2 e12 17415408 10.1371/journal.pctr.0020012
21. Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon. EM Braga RM Barros TA Reis CJ Fontes CG Morais MS Martins AU Krettli, Am J Trop Med Hyg 2002 66 461 466 12201577
22. Antibody responses to Plasmodium falciparum vaccine candidate antigens in three areas distinct with respect to altitude. G Mlambo SL Mutambu T Mduluza W Soko J Mbedzi J Chivenga DE Lanar S Singh D Carucci A Gemperli N Kumar, Acta Trop 2006 100 70 78 10.1016/j.actatropica.2006.09.012 17113021
23. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. SH Quari YP Shi IF Goldman BL Nahlen M Tibayrenc AA Lal, Mol Biochem Parasitol 1998 92 241 252 10.1016/S0166-6851(98)00010-3 9657329
24. DDT, global strategies, and a malaria control crisis in South America. DR Roberts LL Laughlin P Hsheih LJ Legters, Emerg Infect Dis 1997 295 302 9284373
25. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. V Chitarra I Holm GA Bentley S Petres S Longacre, Mol Cell 1999 3 457 464 10.1016/S1097-2765(00) 80473-6 10230398
26. Malaria reemergence in the Peruvian Amazon region. J Aramburu Guarda CR Asayag R Witzig, Emerg Infect Dis 1999 5 209 215 10221872
27. "Adaptive Immunity". RA Goldsby TJ Kindt BA Osborne J Kuby, Immunology New York: W. H. Freeman and Company 5 2003 16 12519298
28. Does malaria suffer from lack of immunity? SS Struik EM Riley, Immunol Rev 2004 268 290 10.1111/j.0105-2896.2004.00181.x 15361247
29. Memory B cell responses and malaria. M Wykes MF Good, Parasite Immunol 2006 28 31 34 10.1111/j.1365-3024.2006.00768.x 16438674
30. Ontogeny of the Immune Response. RR Wagner JK Rose, Baron Medical Microbiology, Baron S, 4 1996
31. Part 13 - The Immunologic System and Disorders. RH Buckley, Behrman Nelson Textbook of Pediatrics Philadelphia: Elsevier Science, Behrman RE, Kliegman R, Jenson HB, 16 2004
32. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. JE Tongren CJ Drakeley SLR McDonald HG Reyburn A Manjurano WMM Nkya MM Lemnge CD Gowds JE Todd PH Corran EM Riley, Infect Immun 2006 74 257 264 16368979 10.1128/IAI.74.1.257-264. 2006
33. Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. OJ Akpogheneta NO Duah KK Tetteh S Dunyo DE Lanar M Pinder DJ Conway, Infect Immun 2008 76 1748 1755 18212081 10.1128/IAI.01333-07
34. Anti-merozoite surface protein-1 19 kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project. OH Branch AJ Oloo BL Nahlen DC Kaslow AA Lal, J Infect Dis 2000 181 1746 1752 10.1086/315424 10823777